Conference Reports for NATAP
International AIDS Conference
Durban, South Africa
July 18-22 2016
Truvada PrEP, Vaginal Ring, Maraviroc PrEP, vaginal
ring att Durban IAC 2016 July 18-22
Efficacy of "On Demand" PrEP in the ANRS IPERGAY Open-Label Extension Study
Integrated delivery of PrEP and ART results in sustained near elimination of HIV transmission in African HIV serodiscordant couples:
Residual dapivirine ring levels indicate higher adherence to vaginal ring is associated with HIV-1 protection ......."Results suggest ring use is associated with at least 56% and potentially >75% protection when used consistently"
Used consistently, monthly vaginal ring may be highly effective against HIV in women, suggest new analyses from ASPIRE
An HIV pre-exposure prophylaxis (PrEP) demonstration project and safety study for adolescent MSM ages 15-17 in the United States (ATN 113)
FTC/TDF (Truvada) for HIV Pre-Exposure Prophylaxis (PrEP) Utilization in the United States: 2012-2015
- (07/20/14) 79,000 used Truvada PrEP since 2012, increased 738%
HPTN 069 / ACTG A5305 Phase II Study of Maraviroc (MVC)-Containing Regimens for HIV PrEP in U.S. Women...."NO new infections....annual incidence rate 0%"
Sexual activity without condoms and risk of HIV transmission when the HIV positive partner is using suppressive ART: The PARTNER study
Changes in Bone Mass after Discontinuation of PrEP with Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC) in Young Men Who Have Sex with Men (YMSM): Extension Phase Results of Adolescent Trials Network (ATN) Study 110